Update on neuropsychiatric symptoms of dementia: Antipsychotic use

Geriatrics

Volumn 64, Issue 5, 2009, Pages 10-18

  Kalapatapu, Raj K ^a   Schimming, Corbett ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotic; Dementia; Evaluation; Management; Symptom; Update

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AGITATION; AGRANULOCYTOSIS; AKATHISIA; ANTICHOLINERGIC EFFECT; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEMENTIA; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENCY; DYSLIPIDEMIA; EXTRAPYRAMIDAL SYMPTOM; GAIT DISORDER; HUMAN; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERPROLACTINEMIA; METABOLIC DISORDER; MORBIDITY; MORTALITY; NEUROLEPTIC MALIGNANT SYNDROME; ORTHOSTATIC HYPOTENSION; PSYCHOSIS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK BENEFIT ANALYSIS; SEDATION; SIDE EFFECT; STROKE; SUDDEN DEATH; TARDIVE DYSKINESIA; WEIGHT GAIN;

AGED; AGGRESSION; ANTIPSYCHOTIC AGENTS; DEMENTIA; GERIATRIC PSYCHIATRY; HUMANS; PIPERAZINES; PSYCHOTIC DISORDERS; QUINOLONES; RISPERIDONE; SEVERITY OF ILLNESS INDEX;

EID: 67649217492     PISSN: 0016867X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Kalapatapu RK, Neugroschl JA. Update on neuropsychiatric symptoms of dementia: Evaluation and management. Geriatrics. 2009;64(4):20-26.
2. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev. 2006:CD003476.
3. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293:596-608.
4. Kindermann SS, Dolder CR, Bailey A, Katz IR, Jeste DV. Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience. Drugs Aging. 2002;19:257-276.
5. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14:191-210.
6. Jeste DV, Blazer D, Casey D, et al. ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology. 2008;33:957-970.
7. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006;355:1525-1538.
8. Rabins PV, Blacker D, Rovner BW, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. Am J Psychiatry. 2007;164(12 Suppl):5-56.
9. Consensus development conference on antipsychotic drugs and obesity and diabetes. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. J Clin Psychiatry. 2004 Feb;65(2):267-272.
10. Salzman C, Jeste DV, Meyer RE, et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J Clin Psychiatry. 2008;69:889-898.
11. Daiello LA. Atypical antipsychotics for the treatment of dementia-related behaviors: an update. Med Health R I. 2007;90:191-194.
12. Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ. 2008;337:al227.
13. Valiyeva E, Herrmann N, Rochon PA, Gill SS, Anderson GM. Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis. CMAJ. 2008;179:438-446.
14. Tiller J, Ames D, Brodaty H, et al. Antipsychotic use in the elderly: what doctors say they do, and what they do. Australas J Ageing. 2008;27:134-142.
15. Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ. 2005;330:445.
16. Herrmann N, Mamdani M, Lanctot KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry. 2004;161:1113-1115.
17. Rochon PA, Normand SL, Gomes T, et al. Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med. 2008;168:1090-1096.
18. Aparasu RR, Jano E, Johnson ML, Chen H, et al. Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients. Am J Geriatr Pharmacother. 2008;6:198-204.
19. Wang PS, Schneeweiss S, Avorn J, et al Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353:2335-2341.
20. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360:225-235.
21. FDA Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. US Food and Drug Administration Web site, http://www.fda. gov/CDER/drug/advisory/antipsychotics. htm. Accessed February 7, 2009.
22. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934-1943.
23. Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146:775-786.
24. Information on Antipsychotics. US Food and Drug Administration Web site. http://www.fda.gov/CDER/drug/infopage/antipsychotics-conventional/default.htm. Accessed January 23, 2009.
25. Ballard C, Hanney ML, Theodoulou M, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol. 2009;8:151-157.
26. Jeste DV, Meeks T. To prescribe or not to prescribe? Atypical antipsychotic drugs in patients with dementia. South Med J. 2007;100:961-963.
27. Schneeweiss S, Avorn J. Antipsychotic agents and sudden cardiac death-how should we manage the risk? N Engl J Med. 2009;360:294-296.
28. Psychopharmacology Research Branch, National Institute of Mental Health. Abnormal Involuntary Movement Scale (AIMS). In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology, Revised. US Dept Health, Education, and Welfare publication ADM 76-338. Rockville, Md: National Institute of Mental Health; 1976. 534-537.